Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Thomas Flaig to Antineoplastic Agents

This is a "connection" page, showing publications Thomas Flaig has written about Antineoplastic Agents.

 
Connection Strength
  
 
 
3.635
  
  1. Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 12; 5(12):3386-3393.
    View in: PubMed
    Score: 0.264
  2. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clin Genitourin Cancer. 2017 04; 15(2):273-279.e1.
    View in: PubMed
    Score: 0.264
  3. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664.
    View in: PubMed
    Score: 0.259
  4. Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 12; 29(12):956-62.
    View in: PubMed
    Score: 0.248
  5. Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol Surg. 2013 Jul; 39(7):981-7.
    View in: PubMed
    Score: 0.205
  6. Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park). 2013 Mar; 27(3):219-26.
    View in: PubMed
    Score: 0.205
  7. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glod? LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 01; 19(1):148-57.
    View in: PubMed
    Score: 0.201
  8. Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012 Dec; 10(4):225-31.
    View in: PubMed
    Score: 0.199
  9. Clemons J, Glod? LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 2013 Feb; 31(2):198-204.
    View in: PubMed
    Score: 0.184
  10. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011 Jul; 78(1):233.e7-13.
    View in: PubMed
    Score: 0.180
  11. Rove KO, Flaig TW. A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park). 2010 Dec; 24(14):1308-13, 1318.
    View in: PubMed
    Score: 0.175
  12. Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep. 2010 Oct; 24(4):1019-28.
    View in: PubMed
    Score: 0.173
  13. Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009 Feb; 27(1):83-7.
    View in: PubMed
    Score: 0.148
  14. Flaig TW, Su LJ, Harrison G, Agarwal R, Glod? LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 01; 120(9):2028-33.
    View in: PubMed
    Score: 0.137
  15. Bowles DW, Flaig TW. Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review. Cancer Invest. 2006 Aug-Sep; 24(5):517-20.
    View in: PubMed
    Score: 0.130
  16. Amirault M, Choo S, Waxweiler T, Weisdack SD, Breaker K, Flaig TW, Lam ET. Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. Cancer Treat Res Commun. 2021; 27:100367.
    View in: PubMed
    Score: 0.090
  17. Castro-Alonso FJ, Dominguez-Pineda J, Rosales-Sotomayor G, Flaig TW, Bourlon MT. Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors. Oncology (Williston Park). 2018 05 15; 32(5):243-6.
    View in: PubMed
    Score: 0.074
  18. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
    View in: PubMed
    Score: 0.073
  19. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
    View in: PubMed
    Score: 0.066
  20. Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb; 27(2):286-94.
    View in: PubMed
    Score: 0.062
  21. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5.
    View in: PubMed
    Score: 0.057
  22. Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May; 49(5):303-15.
    View in: PubMed
    Score: 0.052
  23. Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012 Nov; 29(11):871-83.
    View in: PubMed
    Score: 0.050
  24. Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44.
    View in: PubMed
    Score: 0.050
  25. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl?chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97.
    View in: PubMed
    Score: 0.049
  26. Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr; 97:784-792.
    View in: PubMed
    Score: 0.019
  27. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25.
    View in: PubMed
    Score: 0.012
  28. Siomos VJ, La Rosa FG, Flaig TW, Kondo KL, Mitchell JD, Wilson S, Barqawi AB. Recurrent urothelial carcinoma with pulmonary metastasis. Oncology (Williston Park). 2009 Dec; 23(14):1301-4.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)